Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call

MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release first quarter 2023 financial and operating results prior to market open on Tuesday, May 9th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/dkh33hi3. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 5.3 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.

Investor Contact:
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
ir@neuronetics.com

Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com

Staff

Recent Posts

Therma Bright Closes Second & Final Tranche of Fully Subscribed Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF)…

1 hour ago

SQUID pries open AI black box

COLD SPRING HARBOR, N.Y., June 21, 2024 /PRNewswire/ -- Artificial intelligence continues to squirm its…

2 hours ago

Cenegenics Improves Operational Efficiency with Domo

SILICON SLOPES, Utah--(BUSINESS WIRE)--Domo (Nasdaq: DOMO) announced today that Cenegenics, a leader in the performance…

14 hours ago

Lophos Holdings Inc. Announces the Completion of Securities Purchase Agreement with ThreeD Capital Inc.

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - Lophos Holdings Inc. (CSE: MESC) ("Lophos"…

14 hours ago

Pearl Health CEO Michael Kopko recognized as an EY Entrepreneur Of The Year® 2024 New York Award Winner

NEW YORK, June 20, 2024 /PRNewswire/ -- Ernst & Young LLP (EY US) today announced…

14 hours ago

ProviderTrust Named Top Place to Work by Modern Healthcare and The Tennessean Top Workplaces

NASHVILLE, Tenn., June 20, 2024 /PRNewswire/ -- ProviderTrust was recently selected by Modern Healthcare as one…

14 hours ago